Immunogenetic Management Software: a new tool for visualization and analysis of complex immunogenetic datasets

Abstract

Here we describe the Immunogenetic Management Software (IMS) system, a novel web-based application that permitsmultiplexed analysis of complex immunogenetic traits that are necessary for the accurate planning and execution of experiments involving large animal models, including nonhuman primates. IMS is capable of housing complex pedigree relationships, microsatellite-based MHC typing data, as well as MHC pyrosequencing expression analysis of class I alleles. It includes a novel, automated MHC haplotype naming algorithm and has accomplished an innovative visualization protocol that allows users to view multiple familial and MHC haplotype relationships through a single, interactive graphical interface. Detailed DNA and RNA-based data can also be queried and analyzed in a highly accessible fashion, and flexible search capabilities allow experimental choices to be made based on multiple, individualized and expandable immunogenetic factors. This web application is implemented in Java, MySQL, Tomcat, and Apache, with supported browsers including Internet Explorer and Firefox onWindows and Safari on Mac OS. The software is freely available for distribution to noncommercial users by contacting Leslie. kean@emory.edu. A demonstration site for the software is available at http://typing.emory.edu/typing_demo, user name: imsdemo7@gmail.com and password: imsdemo.

Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention

“…Working to parallel our Top Gene analysis using an approach that can overcome the bias associated with cut-off-based analyses, we performed GSEA(23–25). As depicted in the selected examples in Figure 4a–b and Supplementary Table 3, GSEA analysis identified multiple gene sets that were enriched in the leading edge (left side of figure) of the ranked gene list for No Rx vs Auto controls (transcripts enriched in T cells during GVHD-associated allo-activation).…”

“…Briefly, apheresis was performed after G-CSF mobilization (Amgen, 50mcg/kg for 5 days), and an unmanipulated apheresis product was transplanted into MHC-mismatched recipients. For these studies, we utilized our rhesus macaque MHC typing system(23) to choose donor: recipient pairs, which were all partially MHC-matched, either as half-sibling haplo-identical pairs or as unrelated partially-matched pairs. In the case of the autologous controls, donors were harvested and apheresis products were cryopreserved for a minimum of 2 months prior to the onset of conditioning and subsequent reinfusion of the unmanipulated apheresis product.…”

“…Further analysis of differentiating characteristics between untreated allo-HCT and control arrays involved Gene Set Enrichment Analysis (GSEA) as described(23–25). GSEA can identify whether the members of a gene set (a collection of which are housed in the Molecular Signatures Database (MSig-DB) - Broad Institute, Boston, MA) are enriched in an independent rank-ordered profile of genes that are differentially expressed between two experimental groups.…”

Evidence for Kidney Rejection After Combined Bone Marrow and Renal Transplantation Despite Ongoing Whole-Blood Chimerism in Rhesus Macaques

“…These studies have benefited from a new NIH resource: the NIAID-sponsored MHC-defined primate colony. (19, 34, 42, 43) By studying transplant cohorts with uniform degrees of MHC disparity, we were able to eliminate a critical confounder that has historically plagued NHP transplant studies. We believe that this technical advance has considerably strengthened our ability to draw mechanistic interpretations from our experimental results.…”

Advances in targeting co‐inhibitory and co‐stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy

“…In order to maximize their utility for clinical transplantation, the field of NHP experimentation has greatly benefited from recent advances that help assure that the immune milieu of these transplants is understood in the greatest detail possible. One significant example is the establishment of a new ‘gold standard’ in transplant studies, where the degree of MHC disparity between donors and recipients is now expected to be defined, and equivalent among different treatments in any transplant series . Until 2010, this degree of information about the MHC was not included in transplant planning, which opened up these studies to the potential confounder of serendipitously close MHC matching leading to transplant outcomes that were more successful than they otherwise would have been (or vice versa with highly disparate transplant pairs).…”